AbCellera prices oversubscribed offering at $9.75 a share to raise $200 million

Closing is expected on Aug. 14, 2026, subject to customary conditions.

AbCellera said the proceeds are earmarked for internal pipeline research and development, including its lead clinical program ABCL635, as well as working capital and general corporate purposes.

AbCellera priced an oversubscribed underwritten public offering expected to raise about $200 million in gross proceeds.

The deal includes 17,435,897 common shares priced at $9.75 per share.

The company also issued pre-funded warrants for up to 3,076,926 common shares priced at $9.75 each, with a $0.00001 exercise price.